Inmolecule Nanotech (XPAR:MLINA) Total Stockholders Equity: €7.39 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MLINA Inmolecule Nanotech SA XPAR:MLINA
7 GF Score
Price €4.08
! 2 Warning Signs
View Full Analysis

What is Inmolecule Nanotech Total Stockholders Equity?

Inmolecule Nanotech XPAR:MLINA 7 Total Stockholders Equity is €7.39 Mil as of Dec. 2024. GuruFocus rates XPAR:MLINA with a GF Score™ of 7/100. The stock has 2 warning signs investors should review.

Inmolecule Nanotech's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €7.39 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Inmolecule Nanotech's Book Value per Share for the quarter that ended in Dec. 2024 was €0.99. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Inmolecule Nanotech's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.26.

Inmolecule Nanotech  (XPAR:MLINA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Inmolecule Nanotech's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(7.393-0)/7.500
=0.99

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Inmolecule Nanotech's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.005 + 1.938) / 7.393
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inmolecule Nanotech Total Stockholders Equity Related Terms

Inmolecule Nanotech Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Inmolecule Nanotech's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inmolecule Nanotech Total Stockholders Equity Chart

Inmolecule Nanotech Annual Data
Trend Dec23 Dec24
Total Stockholders Equity
8.54 7.39

Inmolecule Nanotech Semi-Annual Data
Dec23 Dec24
Total Stockholders Equity 8.54 7.39
XPAR:MLINA
7GF Score
Inmolecule Nanotech SA XPAR:MLINA
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €7.39 Mil mean?
Inmolecule Nanotech (XPAR:MLINA) has a Total Stockholders Equity of €7.39 Mil as of Dec. 2024. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Inmolecule Nanotech and its competitors.
Is Inmolecule Nanotech's Total Stockholders Equity too high?
Inmolecule Nanotech's current Total Stockholders Equity is €7.39 Mil. Overall, Inmolecule Nanotech has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's Total Stockholders Equity compare to VRTX and REGN?
Inmolecule Nanotech's Total Stockholders Equity of €7.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Inmolecule Nanotech and its competitors. Inmolecule Nanotech's current Total Stockholders Equity is €7.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (XPAR:MLINA) has a current Total Stockholders Equity of €7.39 Mil. The current Total Stockholders Equity is €7.39 Mil. Inmolecule Nanotech's overall GF Score™ is 7/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Inmolecule Nanotech (XPAR:MLINA), the current Total Stockholders Equity is €7.39 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inmolecule Nanotech Business Description

Address Paseo de la Castellana 91, 4th Floor, Madrid, ESP, 28046
Inmolecule Nanotech SA is a research and development company. The company provides health care, home care and personal care products.
7GF Score

Get the complete analysis for XPAR:MLINA

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price